Table 1

Patient demographics and treatment according to the level of kidney function

DemographicAll patientsNormalMildly reducedModerately reducedSeverely reduced
Cohort77,601 (100)6,038 (100)38,836 (100)31,278 (100)1,449 (100)
Age on index date
 18–34 years419 (0.5)210 (3.5)196 (0.5)10 (0.0)3 (0.2)
 35–44 years3,134 (4.1)946 (15.7)1,973 (5.1)208 (0.7)7 (0.5)
 45–54 years10,498 (13.5)1,923 (31.8)7,109 (18.3)1,405 (4.5)61 (4.2)
 55–64 years20,726 (26.7)1,762 (29.2)12,934 (33.3)5,839 (18.7)191 (13.2)
 65–74 years24,136 (31.1)883 (14.6)11,250 (29.0)11,599 (37.1)404 (27.9)
 75+ years18,688 (24.1)314 (5.2)5,374 (13.8)12,217 (39.1)783 (54.0)
Sex
 Male44,307 (57.1)4,188 (69.4)24,426 (62.9)15,077 (48.2)616 (42.5)
 Female33,294 (42.9)1,850 (30.6)14,410 (37.1)16,201 (51.8)833 (57.5)
Metformin dose
 100 mg276 (0.4)19 (0.3)110 (0.3)138 (0.4)9 (0.6)
 500 mg59,449 (76.6)4,469 (74.0)29,485 (75.9)24,382 (78.0)1,113 (76.8)
 750 mg862 (1.1)63 (1.0)448 (1.2)343 (1.1)8 (0.6)
 850 mg11,707 (15.1)984 (16.3)5,975 (15.4)4,533 (14.5)215 (14.8)
 1,000 mg4,869 (6.3)479 (7.9)2,691 (6.9)1,651 (5.3)48 (3.3)
 Unknown438 (0.6)24 (0.4)127 (0.3)231 (0.7)56 (3.9)
Type of treatment
 Metformin solo36,058 (46.5)2,632 (43.6)17,693 (45.6)15,082 (48.2)651 (44.9)
  With insulin10,298 (13.3)842 (14.0)4,832 (12.4)4,386 (14.0)238 (16.4)
  Without insulin25,760 (33.2)1,790 (29.6)12,861 (33.2)10,696 (34.2)413 (28.5)
 Metformin combo41,543 (53.5)3,406 (56.4)21,143 (54.4)16,196 (51.8)798 (55.1)
  With insulin5,195 (6.7)465 (7.7)2,537 (6.5)2,066 (6.6)127 (8.8)
  Without insulin36,348 (46.8)2,941 (48.7)18,606 (47.9)14,130 (45.2)671 (46.3)
  • Data are n (%).